Axogen | Jotup

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

Retrieved on:

Tuesday, April 16, 2024

ALACHUA, Fla. and TAMPA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2024 financial results on Thursday, May 2, 2024, before the market opens.

Key Points:

ALACHUA, Fla. and TAMPA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2024 financial results on Thursday, May 2, 2024, before the market opens.
Axogen management will host an investment-community conference call and webcast at 8 a.m.
Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or using the direct dial-in number at (201) 689-8795.
Those interested in listening to the conference call live via the Internet may do so by visiting the Investors page of the Company's website at www.axogeninc.com and clicking on the webcast link.

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

Retrieved on:

Tuesday, February 13, 2024

Axogen, Webcast, Nerve, Internet, Cryptocurrency

ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2023 fourth quarter and full-year financial results on Tuesday, March 5, 2024, before the market opens.

Key Points:

ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2023 fourth quarter and full-year financial results on Tuesday, March 5, 2024, before the market opens.
Axogen management will host an investment-community conference call and webcast at 8 a.m.
Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or using the direct dial-in number at (201) 689-8795.
Following the conference call, a replay will be available in the Investors section of the company's website at www.axogeninc.com.

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Retrieved on:

Thursday, January 18, 2024

Visual analogue scale, Axogen, Month, Nerve, Pain, Trial of the century, Neuroma

ALACHUA, Fla. and TAMPA, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced positive topline results from its REPOSE clinical study comparing standard-of-care neurectomy of symptomatic neuroma to neurectomy and protection of the terminated nerve end with Axoguard Nerve Cap. The post-marketing study met its primary endpoint for reduction in pain as measured by visual analog scale (p-value

Key Points:

REPOSE® met its primary endpoint of non-inferiority between the pain visual analog scale outcomes for neurectomy with Axoguard Nerve Cap® vs. standard-of-care neurectomy at Month 12.
Axoguard Nerve Cap demonstrated statistical superiority vs. standard-of-care neurectomy in the reduction of total pain reported by participants over the course of follow-up.
ALACHUA, Fla. and TAMPA, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced positive topline results from its REPOSE clinical study comparing standard-of-care neurectomy of symptomatic neuroma to neurectomy and protection of the terminated nerve end with Axoguard Nerve Cap.
The post-marketing study met its primary endpoint for reduction in pain as measured by visual analog scale (p-value

BioStem Technologies Appoints Proven Life Science Sales Leader Shawn McCarrey to Chief Commercial Officer Role

Retrieved on:

Thursday, January 11, 2024

Senior, Regenerative medicine, History, OTC, Axogen, Bayer, Pharmaceutical industry

(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announces it has appointed a proven life science sales leader, Mr. Shawn McCarrey, as Chief Commercial Officer.

Key Points:

(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announces it has appointed a proven life science sales leader, Mr. Shawn McCarrey, as Chief Commercial Officer.
At Possis Medical, Mr. McCarrey was pivotal in launching 16 new products over a decade, contributing to a substantial 1,158% increase in the company's sales.
Mr. McCarrey said, “BioStem has reached an important inflection point and has a unique opportunity to realize a number of market opportunities in the coming year.
I am very pleased to join BioStem to champion the company’s talented team as it capitalizes on these opportunities.”

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023

Retrieved on:

Thursday, January 4, 2024

Core, Nerve, Growth, Patient, Axogen, BLA, Video game

ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2023 revenue.

Key Points:

ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2023 revenue.
Full-year 2023 revenue is expected to be approximately $158.8 million, which represents a 15% increase over the full-year of 2022.
Revenue from Core Accounts for the full-year 2023 is expected to represent approximately 65% of revenue.
The Company expects to report full, audited results for the fourth quarter and year ended December 31, 2023, on March 5, 2024.

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

Friday, December 1, 2023

ALACHUA and TAMPA, Fla., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced making Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) in connection with the employment and appointment of Harold D. Tamayo as Vice President of Finance and Investor Relations.

Key Points:

ALACHUA and TAMPA, Fla., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced making Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) in connection with the employment and appointment of Harold D. Tamayo as Vice President of Finance and Investor Relations.
Mr. Tamayo will report to Peter J. Mariani, Executive Vice President and Chief Financial Officer, and will be responsible for Financial Planning and Analysis and Investor Relations.
Most recently he served as Interim CFO of Neighborhood LTC Pharmacy, a technology healthcare management and pharmacy company in Lincoln, NE.
Prior to this he served as SVP Corporate Finance, M&A, Investor Relations for McKesson, a diversified healthcare company.

Axogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare Conference

Retrieved on:

Monday, November 20, 2023

Piper Sandler Companies, Axogen, Conference, Nerve

ALACHUA and TAMPA, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, Chairman, Chief Executive Officer, and President, will present at the Piper Sandler 35th Annual Healthcare Conference in New York, NY, on Thursday, November 30, 2023, at 8:50 a.m. E.T.

Key Points:

ALACHUA and TAMPA, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, Chairman, Chief Executive Officer, and President, will present at the Piper Sandler 35th Annual Healthcare Conference in New York, NY, on Thursday, November 30, 2023, at 8:50 a.m. E.T.
Webcast events can be accessed live through the Investors page at www.axogeninc.com.
For those not available to listen to the live broadcast, the replay will be archived for 90 days and available through the Investors page on www.axogeninc.com.

J.Jill Appoints Maria Martinez as Chief Human Resources Officer

Retrieved on:

Monday, November 13, 2023

Retail, Professional Services, Human Resources, Fashion, Woman, CHRO, Acquisition, NYSE, Organization, Creativity, Workforce, Culture, HSN, Martínez, HR, Growth, Axogen

J.Jill, Inc. (NYSE:JILL), a premier omnichannel retailer and national lifestyle brand, has announced the appointment of Maria Martinez as its Chief Human Resources Officer (CHRO), effective immediately.

Key Points:

J.Jill, Inc. (NYSE:JILL), a premier omnichannel retailer and national lifestyle brand, has announced the appointment of Maria Martinez as its Chief Human Resources Officer (CHRO), effective immediately.
In this role, Martinez will lead J.Jill’s human resources function and strategy, including talent acquisition and retention, corporate and retail business partners, culture and engagement, diversity, equity, and inclusion, corporate communications, and total rewards.
“With over two decades of experience developing and implementing impactful human resources programs and strategies, Maria will be instrumental in our business-focused people strategy,” said Claire Spofford, President and CEO of J.Jill.
At HSNi, Martinez oversaw talent acquisition, career and succession development, culture and engagement, and total rewards.

Axogen, Inc. Reports 2023 Third Quarter Financial Results

Retrieved on:

Tuesday, November 7, 2023

FDA, Biologics license application, EBITDA, Nerve, Internet, Trauma, Extracellular matrix, APC, Axogen, Growth, Webcast, ECM, Investment, Patient, BLA, Clothing, Video game

Revenue was $41.3 million during the third quarter, an increase of approximately 12% over the third quarter of 2022.

Key Points:

Revenue was $41.3 million during the third quarter, an increase of approximately 12% over the third quarter of 2022.
Gross margin was 80.5% for the quarter, compared to 83.3% in the third quarter of 2022.
The balance of all cash and cash equivalents and investments on September 30, 2023, was $38.6 million, compared to $40.8 million on June 30, 2023.
Ended the quarter with 116 direct sales representatives compared to 115 on June 30, 2023, and 111 a year ago.

Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023

Retrieved on:

Wednesday, October 18, 2023

Axogen, Nerve, Webcast, Internet, Cryptocurrency

ALACHUA, Fla. and TAMPA, Fla., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter 2023 financial results on Tuesday, November 7, 2023 before the market opens.

Key Points:

ALACHUA, Fla. and TAMPA, Fla., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter 2023 financial results on Tuesday, November 7, 2023 before the market opens.
Axogen management will host an investment-community conference call and webcast at 8:00 a.m.
Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or using the direct dial-in number at (201) 689-8795.
Following the conference call, a replay will be available in the Investors section of the company's website at www.axogeninc.com.